Efficacy of monensin sodium for the reduction of fecal shedding of Mycobacterium avium subsp. paratuberculosis in infected dairy cattle.
Reducing the quantity of Mycobacterium avium subsp. paratuberculosis (MAP) being shed by cows with Johne's disease should decrease the risk of spread of this disease to young stock. Previous work has suggested that monensin sodium decreases the pathologic lesions associated with Johne's disease, but the impact on shedding of viable MAP remains unknown. After serologic screening of 32 dairy herds in southwestern Ontario, 228 cows from 13 of these herds were enrolled into a randomized clinical trial. Fecal culture and PCR were used to identify 114 cows as potential fecal shedders, while another 114 cows were enrolled as ELISA negative, herd and parity matched controls. All cows were randomized to receive either a monensin controlled release capsule (CRC) or a placebo capsule. Serial fecal and blood samples were collected for fecal culture and serum ELISA testing over a 98-day period. On day 98 of the study, treatments were switched for all cows continuing in the trial. These remaining cows were followed for another 98 days with a similar sampling protocol. Mixed effect models were used to measure the impact of treatment on the number of colony forming units identified on fecal cultures over time. During the first 98 days of the study, cows treated with a monensin CRC were found to shed 3.4cfu per tube less than placebo treated cows (P=0.05). The serum ELISA S/P ratio was reduced by 1.39 units in cows given monensin (P=0.06). However, treatment with monensin did not reduce the odds of testing positive on serology. Only the cows shedding MAP on day 0 were found to have a reduced odds of testing positive on fecal culture when treated with monensin (OR=0.27; P=0.03). Monensin sodium administered to infected animals at 335mg/day marginally reduced fecal shedding of MAP in mature dairy cattle, but the biological significance of this reduction is unknown.
Hendrick
Steven H
SH
Department of Large Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Sask., Canada S7N 5B4. steve.hendrick@usask.ca
Kelton
David F
DF
Leslie
Ken E
KE
Lissemore
Kerry D
KD
Archambault
Marie
M
Bagg
Randy
R
Dick
Paul
P
Duffield
Todd F
TF
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D015169:Colony Count, Microbial / Q000662:veterinary; D018592:Cross-Over Studies; D005243:Feces / Q000382:microbiology; D005260:Female; D008985:Monensin / Q000627:therapeutic use*; D016927:Mycobacterium avium subsp. paratuberculosis / Q000187:drug effects* / Q000276:immunology; D009864:Ontario; D010283:Paratuberculosis / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D008985:Monensin